Literature DB >> 12527664

NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function.

M Bay1, V Kirk, J Parner, C Hassager, H Nielsen, K Krogsgaard, J Trawinski, S Boesgaard, J Aldershvile.   

Abstract

OBJECTIVE: To evaluate whether measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) can be used to differentiate patients with normal and reduced left ventricular ejection fraction (LVEF) in an unselected consecutive group of hospital inpatients.
SETTING: City general hospital, Copenhagen, Denmark. PATIENTS AND
DESIGN: During a 10 month period 2230 admissions to a city general hospital (80% of targeted patients) had an echocardiographic evaluation of left ventricular function, a comprehensive clinical evaluation, and blood analysis of N-terminal-pro-brain natriuretic peptide (NT-proBNP) within 24 hours of admission. Exclusions resulted from lack of informed consent or failure to obtain the required evaluations before death or discharge from hospital. Echocardiography was unsatisfactory in 37 patients, so the final number studied was 2193.
RESULTS: A raised NT-proBNP (>or= 357 pmol/l) identified patients with an LVEF of <or= 40% (n = 157) with a sensitivity of 73% and a specificity of 82%. The negative predictive value of having an NT-proBNP concentration below 357 pmol/l was 98%. Concentrations of NT-proBNP increased with increasing age and with decreasing LVEF (p < 0.05). A predicted concentration of NT-proBNP (corrected for age, sex, and serum creatinine) was determined for each patient. In patients with an NT-proBNP value less than predicted, the probability of having an LVEF of > 40% was more than 97%. This probability rapidly decreased to 70% as the measured NT-proBNP increased to 150% of the predicted value.
CONCLUSIONS: A single measurement of NT-proBNP at the time of hospital admission provides important information about LVEF in unselected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527664      PMCID: PMC1767525          DOI: 10.1136/heart.89.2.150

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  28 in total

1.  Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis.

Authors:  J Berning; J Rokkedal Nielsen; J Launbjerg; J Fogh; H Mickley; P E Andersen
Journal:  Cardiology       Date:  1992       Impact factor: 1.869

2.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

Authors:  L E Teichholz; T Kreulen; M V Herman; R Gorlin
Journal:  Am J Cardiol       Date:  1976-01       Impact factor: 2.778

3.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  The natural history of congestive heart failure: the Framingham study.

Authors:  P A McKee; W P Castelli; P M McNamara; W B Kannel
Journal:  N Engl J Med       Date:  1971-12-23       Impact factor: 91.245

5.  Evaluation of brain natriuretic peptide in the diagnosis of heart failure.

Authors:  P Bettencourt; A Ferreira; P Dias; A Castro; L Martins; M Cerqueira-Gomes
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

6.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.

Authors:  Q Dao; P Krishnaswamy; R Kazanegra; A Harrison; R Amirnovin; L Lenert; P Clopton; J Alberto; P Hlavin; A S Maisel
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

8.  Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease.

Authors:  A M Richards; I G Crozier; T G Yandle; E A Espiner; H Ikram; M G Nicholls
Journal:  Br Heart J       Date:  1993-05

9.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

10.  Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.

Authors:  P Kinnunen; O Vuolteenaho; H Ruskoaho
Journal:  Endocrinology       Date:  1993-05       Impact factor: 4.736

View more
  32 in total

Review 1.  Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.

Authors:  R Senior; G Galasko; J V McMurray; J Mayet
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

2.  Amino-terminal pro-brain natriuretic peptid in prediction of left ventricular ejection fraction.

Authors:  Mugdim Bajrić; Fahir Baraković; Zumreta Kusljugić; Nermin Salkić; Elmir Jahić; Mensura Ascerić; Farid Ljuca; Denis Mrsić; Elnur Smajić; Jasmin Caluk; Ramiz Hajrić
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

3.  Standard measures for sickle cell disease research: the PhenX Toolkit sickle cell disease collections.

Authors:  James R Eckman; Kathryn L Hassell; Wayne Huggins; Ellen M Werner; Elizabeth S Klings; Robert J Adams; Julie A Panepinto; Carol M Hamilton
Journal:  Blood Adv       Date:  2017-12-15

4.  Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Authors:  Borut Jug; Miran Sebestjen; Miso Sabovic; Maja Pohar; Irena Keber
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial.

Authors:  Quynh A Truong; Emily Siegel; Mahir Karakas; James L Januzzi; Fabian Bamberg; Amir A Mahabadi; Selcuk Dasdemir; Thomas J Brady; Andreas Bergmann; Jan Kunde; John T Nagurney; Udo Hoffmann; Wolfgang Koenig
Journal:  Clin Chem       Date:  2010-02-25       Impact factor: 8.327

6.  Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study.

Authors:  Christian A Schmittinger; Christian Torgersen; Günter Luckner; Daniel C H Schröder; Ingo Lorenz; Martin W Dünser
Journal:  Intensive Care Med       Date:  2012-04-12       Impact factor: 17.440

7.  Age and Sex Distributions of Age-Related Biomarker Values in Healthy Older Adults from the Long Life Family Study.

Authors:  Paola Sebastiani; Bharat Thyagarajan; Fangui Sun; Lawrence S Honig; Nicole Schupf; Stephanie Cosentino; Mary F Feitosa; Mary Wojczynski; Anne B Newman; Monty Montano; Thomas T Perls
Journal:  J Am Geriatr Soc       Date:  2016-10-26       Impact factor: 5.562

8.  Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.

Authors:  Krithika Srikanthan; Rebecca Klug; Maria Tirona; Ellen Thompson; Haresh Visweshwar; Nitin Puri; Joseph Shapiro; Komal Sodhi
Journal:  J Clin Exp Cardiolog       Date:  2017-03-22

9.  Cardiac and Carotid Markers Link With Accelerated Brain Atrophy: The AGES-Reykjavik Study (Age, Gene/Environment Susceptibility-Reykjavik).

Authors:  Behnam Sabayan; Mark A van Buchem; Sigurdur Sigurdsson; Qian Zhang; Osorio Meirelles; Tamara B Harris; Vilmundur Gudnason; Andrew E Arai; Lenore J Launer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-08       Impact factor: 8.311

10.  Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis.

Authors:  Simona L Bar; Elizabeth Swiggum; Lynn Straatman; Andrew Ignaszewski
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.